PresentationOkay. We're going to get started. So next up, we're pleased to welcome Colgate's CEO, Noel Wallace, to the stage. Noel is going to start with a presentation highlighting the success of Colgate's 2025 strategic plan, give us a little peek into a few topics of the 2030 strategy. And then after that, I'll come back on stage for a brief Q&A.Noel WallaceChairman, CEO & President Well, thank you, Lauren, and good morning, everyone. A reminder, I'm sure you've seen this a couple of times already. Okay. ...

Colgate-Palmolive Company (CL) FY 2025 Conference September 03, 2025 09:00 AM ET Company ParticipantsLauren Lieberman - Managing DirectorNoel Wallace - Chairman, CEO & PresidentLauren LiebermanOkay. We're going to get started. So next up, we're pleased to welcome Colgate's CEO, Noel Wallace, to the stage. Noel is going to start with a presentation highlighting the success of Colgate's 2025 strategic plan, give us a little peek into a few topics of the 2030 strategy, and then after that, I'll come back on st ...

Colgate-Palmolive Company (CL) FY 2025 Conference September 03, 2025 09:00 AM ET Speaker0Okay. We're going to get started. So next up, we're pleased to welcome Colgate's CEO, Noel Wallace, to the stage. Noel is going to start with a presentation highlighting the success of Colgate's 2025 strategic plan, give us a little peek into a few topics of the 2030 strategy, and then after that, I'll come back on stage for a brief Q and A.Speaker1Well, thank you, Yvonne, and good morning, everyone. A reminder, I'm sur ...

Barclays Global Consumer Staples Conference September 3, 2025 © 2025 Colgate-Palmolive Company TEAM NAME September 2025 Notice for Investor Presentation Please review the following presentation in conjunction with our second quarter 2025 earnings press release, our second quarter 2025 prepared management remarks and additional information regarding our non-GAAP financial measures. Our presentation contains non- GAAP financial measures, which differ from our reported results prepared in accordance with U.S. ...

Core Insights - Procter & Gamble (PG) and Colgate-Palmolive (CL) are two dominant players in the consumer goods industry, each with distinct market strategies and brand positioning [1][3] - PG focuses on a diversified portfolio across various categories, while CL specializes in oral care and leverages consumer trust [2][4] Procter & Gamble (PG) - PG has a vast and diversified portfolio that includes beauty, grooming, healthcare, and home care, allowing it to maintain a strong presence in both developed and emerging markets [4][6] - The company's growth model emphasizes "irresistible superiority," enhancing product performance, packaging, communication, retail execution, and value to drive consumer loyalty [5][6] - In fiscal 2025, PG's organic sales increased by 2% year over year, supported by productivity savings of $2.7 billion, which were reinvested in innovation and brand-building [7] - PG's focus on key demographics and digital tools has strengthened its marketing efficiency and engagement with younger consumers [6][7] - The Zacks Consensus Estimate for PG's fiscal 2026 sales and EPS indicates growth of 3.2% and 2.3%, respectively, although EPS estimates have slightly decreased recently [12][15] Colgate-Palmolive (CL) - CL holds a significant market share in oral care, with 32.7% in the U.S. toothpaste market and 42.3% in manual toothbrushes, while also diversifying into personal care and pet nutrition [8][10] - The company is focused on premiumization and digital innovation, rolling out differentiated products and enhancing its marketing efficiency through AI and data analytics [9][10] - In the second quarter of 2025, CL reported net sales of $5.1 billion, with organic sales rising by 1.8% year over year despite challenges from currency and commodity inflation [11] - The Zacks Consensus Estimate for CL's 2025 sales and EPS suggests growth of 1.4% and 2.2%, respectively, with recent upward revisions in EPS estimates indicating stronger near-term confidence [12][15] Comparative Analysis - Both PG and CL have faced share price declines this year, with PG down 6.3% and CL down 7.5%, but both are trading below historical valuation levels, presenting attractive entry points for investors [17][21] - PG's forward P/E multiple is 22.23X, while CL's is 21.85X, both below their respective five-year medians [19][21] - While PG maintains a broader long-term growth narrative, CL shows stronger near-term momentum with upward EPS revisions, indicating a shift in investor sentiment [15][16][24] Conclusion - PG remains a strong player with unmatched scale and a diversified portfolio, but its earnings outlook has softened slightly [23] - CL presents a more attractive near-term investment opportunity with upward revisions in earnings estimates and a focus on affordability and growth prospects [24]

Group 1 - Zacks Premium offers various tools for investors, including daily updates on Zacks Rank and Industry Rank, access to the Zacks 1 Rank List, Equity Research reports, and Premium stock screens to enhance investment confidence [1][2] - The Zacks Style Scores rate stocks based on value, growth, and momentum characteristics, providing complementary indicators to the Zacks Rank [2][3] Group 2 - The Value Score focuses on identifying undervalued stocks using ratios like P/E, PEG, and Price/Sales to highlight attractive investment opportunities [3] - The Growth Score assesses a company's financial strength and future outlook by examining projected and historical earnings, sales, and cash flow [4] - The Momentum Score helps investors capitalize on price trends by analyzing one-week price changes and monthly earnings estimate changes [5] Group 3 - The VGM Score combines all three Style Scores, offering a comprehensive indicator for investors seeking the best value, growth, and momentum stocks [6] - The Zacks Rank utilizes earnings estimate revisions to help investors build successful portfolios, with 1 (Strong Buy) stocks achieving an average annual return of +23.75% since 1988, outperforming the S&P 500 [7][9] Group 4 - Colgate-Palmolive Company is focused on increasing its leadership in key product categories through innovation and expansion into new markets, particularly in response to consumer preferences for organic and natural ingredients [11] - Colgate-Palmolive has a Zacks Rank of 3 (Hold) and a VGM Score of B, with a Growth Style Score of B indicating a forecasted year-over-year earnings growth of 2.2% for the current fiscal year [12] - The Zacks Consensus Estimate for Colgate-Palmolive has increased by $0.03 to $3.68 per share, with seven analysts revising their earnings estimates upwards in the last 60 days [12][13]

Core Strategy - Colgate-Palmolive Company's innovation strategy for 2025 aims to boost market share amid macroeconomic challenges by focusing on impactful innovation, data analytics, AI, and omni-channel demand generation to support its 2030 strategic plan [1][4] - The company is introducing core and premium products across regions to enhance brand health and household penetration, with notable launches in oral care such as Colgate Max White Clinical in the U.K. and Miracle Repair serum-infused toothpaste in China [1][2] Product Innovation - The innovation drive extends beyond oral care to personal and home care, as well as Hill's Pet Nutrition, with products like Sanex Skin Therapy in Europe and relaunches of Protex bar soap and Suavitel Superior Care in Latin America [2] - In the Hill's Pet Nutrition segment, innovations like ActivBiome+ Multi-Benefit in Science Diet target niche therapeutic needs, appealing to veterinarians and pet owners [2] Premiumization Strategy - Colgate's approach includes premiumization to capture higher-margin sales and differentiate from value-tier competitors, with brands like Colgate Total and elmex leading premium growth in markets like Latin America and Europe [3] - The company maintains robust advertising investment over 13% of net sales to reinforce consumer awareness and trust amid intense competition [3] Future Outlook - The 2025 guidance acknowledges weaker category growth in the first half and potential raw material inflation headwinds, but management expects innovation-led volume gains and targeted pricing strategies to offset these pressures [4] - If executed effectively, Colgate's innovation pipeline across various segments could serve as a primary catalyst for market share gains in 2025, enhancing its competitive positioning in both mature and emerging markets [4] Competitive Landscape - Key competitors in the global market include Church & Dwight, Procter & Gamble, and Clorox, each driving growth through their own innovation strategies [5][6][7][8] - Church & Dwight focuses on both premium and value segments, while Procter & Gamble leverages a "superiority" strategy with digital-first marketing [6][7] - Clorox emphasizes value-driven offerings and sustainability across its portfolio, aiming to strengthen brand relevance and capture new users [8][9]

Core Viewpoint - Several countries in Latin America, including Brazil, Argentina, Colombia, and Mexico, have banned the sale of Colgate's toothpaste due to potential adverse reactions such as gum swelling [2] Group 1: Product and Regulatory Issues - Colgate's product "Colgate Total Advanced Protection Clean Mint" is not sold in mainland China, and the company is withdrawing it from retail stores in Latin America but will not initiate a consumer recall [2] - The Brazilian National Health Surveillance Agency indicated that consumer discomfort may be related to stannous fluoride in the toothpaste, which has antibacterial and anti-cavity properties [2][3] - Stannous fluoride is a type of fluoride that can be used in toothpaste, but regulations require it to be added in limited quantities, with a maximum concentration of 0.15% [3] Group 2: Financial Performance - Colgate-Palmolive's net sales for the first half of the year decreased by 1.02% to $10.021 billion, while net profit increased by 1.34% to $1.433 billion [3] - Latin America is the largest revenue market for Colgate, accounting for 23% of revenue and 33% of operating profit in the first half of 2025 [3]

Core Viewpoint - Colgate's toothpaste has been banned in Mexico and several Latin American countries due to reports of adverse reactions such as gum swelling and oral pain [1][2][3][4][5]. Group 1: Product Recall and Consumer Safety - The Mexican Federal Health Risk Protection Committee announced a recall of "Colgate Total Prevención Activa Clean Mint" toothpaste, advising consumers to stop using it due to potential adverse effects [2]. - Reports indicate that the toothpaste may cause symptoms including oral irritation, gum swelling, and allergic reactions [2][3]. - Colgate-Palmolive has issued an apology and stated that all its products comply with local health regulations, emphasizing the safety and quality of its products [1][5]. Group 2: Regional Impact and Regulatory Actions - The toothpaste has been banned in Brazil, Argentina, and Colombia, with Brazil's health authority citing a higher incidence of adverse reactions linked to the product's formulation [3][4]. - In Argentina, 19 adverse event reports were received, while Brazil reported 11,441 cases since the product's launch in July 2024 [4]. - Colombia's health authority identified harmful fragrances in the toothpaste, leading to its ban [5]. Group 3: Financial Performance and Market Position - Colgate-Palmolive reported a 1.02% decline in net sales to $10.021 billion in the first half of 2025, with Latin America being the largest revenue market, accounting for 23% of total revenue [7]. - The company's gross margin slightly increased to 60.4%, while operating profit from Latin America represented 33% of the total [7]. - The Asia-Pacific region saw a 2.13% decline in revenue, indicating challenges in maintaining market share [7].

Core Viewpoint - Ahold NV (ADRNY) is currently viewed as a more attractive investment compared to Colgate-Palmolive (CL) based on various valuation metrics and analyst outlooks [1][3]. Valuation Metrics - ADRNY has a forward P/E ratio of 13.52, significantly lower than CL's forward P/E of 23.05, indicating that ADRNY may be undervalued [5]. - The PEG ratio for ADRNY is 1.67, while CL's PEG ratio is much higher at 4.41, suggesting that ADRNY offers better value relative to its expected earnings growth [5]. - ADRNY's P/B ratio stands at 2.29, compared to CL's P/B ratio of 65.08, further highlighting ADRNY's relative undervaluation [6]. Analyst Ratings - ADRNY holds a Zacks Rank of 1 (Strong Buy), indicating a positive earnings estimate revision trend, while CL has a Zacks Rank of 3 (Hold) [3][6]. - The Value grade for ADRNY is A, whereas CL has a Value grade of C, reinforcing the notion that ADRNY is the better option for value investors [6].